Amendments to the Claims

1-88. (Cancelled)

89. (Currently Amended) A fast-dissolving pharmaceutical composition in a solid dosage form ~~excepting a nanoparticle suspension~~, comprising micronized (R)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (hereinafter referred to as "AS-3201") having a mean particle size of in a range of ~~above 1~~ about 1.5 μm to less than about 10 μm in a ratio of about 0.5% by weight to about 25% by weight of the total weight of the pharmaceutical composition, and as a stabilizer at least one acidic substance having a pKa less than about 5.6,

wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved with l5 minutes from the start of the method.

90. (Currently Amended) The fast-dissolving pharmaceutical composition according to claim 89, wherein the acidic substance is ~~tartaric acid.~~ a member selected from the group consisting of citric acid, tartaric acid, maleic acid and phosphoric acetate.

91-113. (Cancelled)

114. (Previously presented) The fast-dissolving pharmaceutical composition according to claim 89, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μm to about 5 μm.

115. (Cancelled)

116. (Previously presented) The fast-dissolving pharmaceutical composition according to claim 89, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μm to about 3 μm.

117. (Previously presented) The fast-dissolving pharmaceutical composition according to claim 89, wherein the solid dosage form is tablets, capsules, granules or powder.

118. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the acidic substance is tartaric acid.